Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 14, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-21
DOI
10.1186/s13045-021-01077-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older
- (2021) Lucie Oberic et al. JOURNAL OF CLINICAL ONCOLOGY
- Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
- (2021) Sakshi Jasra et al. Experimental Hematology & Oncology
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
- (2020) Stephen J Schuster et al. BLOOD
- Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia
- (2020) Ola A. Elgamal et al. Journal of Hematology & Oncology
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
- (2020) Elias Jabbour et al. AMERICAN JOURNAL OF HEMATOLOGY
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax
- (2020) Victor S Lin et al. BLOOD
- Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma With Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
- (2020) Yuqin Song et al. CLINICAL CANCER RESEARCH
- Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
- (2020) Sham Mailankody et al. JOURNAL OF CLINICAL ONCOLOGY
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Genomic Mosaicism in Multiple Myeloma
- (2020) Christine J. Ye et al. Frontiers in Genetics
- Recent advances in CAR-T cell engineering
- (2020) Ruihao Huang et al. Journal of Hematology & Oncology
- Role of CD47 in Hematological Malignancies
- (2020) Entsar Eladl et al. Journal of Hematology & Oncology
- Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
- (2020) Gilles Salles et al. LANCET ONCOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in targeted therapy for acute myeloid leukemia
- (2020) Jifeng Yu et al. Biomarker Research
- Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies
- (2020) Yuru Nie et al. Biomarker Research
- Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia
- (2020) Lindsey T. Brinton et al. Journal of Hematology & Oncology
- BCMA-targeted immunotherapy for multiple myeloma
- (2020) Bo Yu et al. Journal of Hematology & Oncology
- Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
- (2020) Musa Yilmaz et al. Journal of Hematology & Oncology
- Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
- (2020) Michael W. Deininger et al. Journal of the National Comprehensive Cancer Network
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
- (2020) Robin Foà et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs
- (2020) Andreas Hochhaus et al. BLOOD
- Novel therapeutics in myeloproliferative neoplasms
- (2020) Sangeetha Venugopal et al. Journal of Hematology & Oncology
- Natural killer cell-based immunotherapy for acute myeloid leukemia
- (2020) Jing Xu et al. Journal of Hematology & Oncology
- Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
- (2020) Ahmet Yilmaz et al. Journal of Hematology & Oncology
- Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity
- (2020) Tracy C. Kuo et al. Journal of Hematology & Oncology
- Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent
- (2020) Nur Najmi Mohamad Anuar et al. Frontiers in Pharmacology
- Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
- (2019) Delong Liu et al. Journal of Hematology & Oncology
- Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
- (2019) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells
- (2019) Amin Kamrani et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
- (2019) Bo Yu et al. Journal of Hematology & Oncology
- Recent updates on CAR T clinical trials for multiple myeloma
- (2019) Quande Lin et al. Molecular Cancer
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial
- (2018) Jorge E. Cortes et al. BLOOD
- Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
- (2018) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
- (2018) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
- (2018) Hagop Kantarjian et al. LANCET ONCOLOGY
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immune therapy for myeloid malignancies: present and future
- (2018) Morten Orebo Holmström et al. Seminars in Immunopathology
- Momelotinib therapy for myelofibrosis: a 7-year follow-up
- (2018) Ayalew Tefferi et al. Blood Cancer Journal
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
- (2018) Frederick L Locke et al. LANCET ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
- (2017) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
- (2017) Andrew A. Wylie et al. NATURE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia
- (2015) N. V. Frey et al. BLOOD
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
- (2015) M. L. Wang et al. BLOOD
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
- (2015) M Pfirrmann et al. LEUKEMIA
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now